報價延遲最少15分鐘:2024/12/24 13:10 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
7.86 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.48/-2.65
|
|
企業價值
874.65M
|
| 資產負債 |
|
每股賬面淨值
1.85
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/24 13:10 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. |